Public investors see opportunity for drug startups to be acquired Biotechnology startups are commanding higher prices in their initial public offerings, a sign of investors’ growing faith in small drugmakers.
When Vas Narasimhan started as the new CEO of Swiss drug giant Novartis, he began refocusing the company on a key business area: prescription medicines. Until recently, alongside top-selling psoriasis,
LONDON/FRANKFURT (Reuters) - British fund manager Neil Woodford is looking to kick off the sale of his unlisted biotech investments at the end of July, but faces months of negotiations to offload the a
Embattled fund manager Neil Woodford could start offloading holdings in unlisted biotech companies at the end of this month, although it remains unclear how long the sales will take or when investors have